Live News • Jul 29
FDA Clears Dyne Therapeutics IND for DYNE-302 Clinical Trial in FSHD Dyne Therapeutics received U.S. FDA clearance of its Investigational New Drug application for DYNE-302, allowing initiation of a Phase 1 multiple ascending dose trial in ambulatory adults with facioscapulohumeral muscular dystrophy that will assess safety, tolerability, pharmacokinetics and pharmacodynamics while targeting DUX4 expression in muscle.
The DYNE-302 program uses Dyne Therapeutics’ FORCE platform and represents another clinical-stage effort focused on functional improvement in FSHD, a neuromuscular disease with significant unmet medical need.
Dyne Therapeutics’ stock trades at $25.90, with a 40.0% return year to date, which frames this regulatory milestone against already strong recent share price performance.
This IND clearance shifts DYNE-302 from a preclinical asset into the clinic, a stage that often becomes a key focus for biotech investors tracking pipeline execution risk and upcoming trial readouts. Announcement • Jul 28
Dyne Therapeutics, Inc. Receives U.S. FDA Clearance For IND Application For DYNE-302 In Facioscapulohumeral Muscular Dystrophy Dyne Therapeutics, Inc. has received clearance from the U.S. Food and Drug Administration for its IND application to initiate a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy. DYNE-302 leverages the same FORCE platform as Dyne’s first two clinical programs, zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in exon 51 Duchenne muscular dystrophy and zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in myotonic dystrophy type 1. FSHD is a rare, progressive, inherited muscle disease with no approved therapies. De-repression of DUX4 in skeletal muscle drives disease pathogenesis, leading to muscle damage and loss of function. DYNE-302 is designed to leverage a TfR1-targeting Fab for muscle delivery of an siRNA payload highly specific for DUX4 mRNA with the aim of suppressing DUX4 expression and the downstream DUX4 transcriptome. In preclinical models of FSHD, administration of DYNE-302 resulted in robust knockdown of the DUX4 transcriptome in skeletal muscle, significant reversal of muscle fiber damage and functional improvement in a severe disease model. These findings suggest that preexisting skeletal muscle damage in FSHD has the potential to be reversed by targeting DUX4 mRNA with DYNE-302. Dyne plans to evaluate DYNE-302 in a Phase 1 randomized, placebo-controlled, double-blind, multiple ascending dose clinical trial in ambulatory adult individuals with FSHD. The primary endpoint will be safety and tolerability. The trial will also assess pharmacokinetics and pharmacodynamics, including change from baseline in muscle DUX4 transcriptome and plasma KHDC1L levels, which Dyne has independently identified as a DUX4-regulated biomarker in FSHD. In the first cohort, 9 participants will receive three intravenous doses administered every four weeks, randomized 2:1 to DYNE-302 1.5 mg/kg or placebo. Following the completion of this cohort, Dyne intends to evaluate higher dosing and less frequent administration. Participants who complete the placebo-controlled period may enter an open-label long-term extension and receive DYNE-302 for up to an additional 96 weeks. Dyne intends to pursue a traditional approval pathway in the U.S. for DYNE-302. DYNE-302 is an investigational therapeutic for people living with FSHD. DYNE-302 consists of an antigen-binding fragment that binds to the transferrin receptor 1, conjugated to an siRNA designed to reduce DUX4 expression. Dyne has generated extensive preclinical data that demonstrate robust and durable DUX4 suppression and functional improvement in a preclinical in vivo model of FSHD developed by Dyne. FSHD is a rare, progressive, genetic disease caused by a mutation in the DUX4 gene, leading to skeletal muscle loss, muscle weakness and wasting. Individuals with FSHD carry a genetic mutation that allows the DUX4 gene to be sporadically activated in muscle cells, causing their gradual destruction throughout the body. People living with FSHD experience weakness in all major muscle groups throughout the body and limited mobility. An estimated 15,000 to 40,000 individuals in the United States and approximately 20,000 to 50,000 in Europe are affected by FSHD, but there are currently no approved therapies. New Risk • Jul 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$320m net loss in 3 years). 
